
George Schett
Professor of Internal Medicine and Vice President for Research at Friedrich-Alexander University Erlangen-Nürnberg; pioneer of CAR-T cell therapy for autoimmune diseases including lupus and rheumatoid arthritis.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
Jun 2, 2026
Cell Therapy in Rheumatology: CAR-T vs Regulatory T Cells
11:14
11:29
11:43
12:07
12:20
17:25

John HausmanHOST
Talk a little bit about what other diseases you think are particularly suitable for CAR T-cell therapy and then some of the other additional trials that you've led based on your previous work.

George SchettGUEST
Yeah, but in the rheumatology arena, I would say there are a couple of other diseases where there is interest in CAR T-cell therapy.

George SchettGUEST
Both of them have substantial disease burden, potentially being life-threatening due to lung and heart involvement and limited therapeutic options, right? And while some of the patients are doing well with current treatment and there is also some substantial progress in these two diseases in the last years, there's still an unmet need, I would say, for severe and resistant cases.

George SchettGUEST
The initial data also from several different groups have now shown that there is a substantial effect on lung and skin disease in systemic sclerosis and on muscle and lung disease in different forms of autoimmune myositis.

George SchettGUEST
So there is actually hope that the data in lupus are transferable to these two severe rheumatic diseases.

John HausmanHOST
I wonder your thoughts about Tregs and sort of CAR-T and could that be a potential option for managing, for treating patients with autoimmune disease?